Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Childhood rhabdomyosarcoma: new insight on biology and treatment.

Huh WW, Skapek SX.

Curr Oncol Rep. 2010 Nov;12(6):402-10. doi: 10.1007/s11912-010-0130-3. Review.

PMID:
20820958
2.

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.

Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, Gronchi A, Olmi P, Fossati-Bellani F, Casali PG.

Cancer. 2003 Aug 1;98(3):571-80. Review.

3.

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O.

J Clin Oncol. 2010 May 1;28(13):2151-8. doi: 10.1200/JCO.2009.26.3814. Epub 2010 Mar 29.

PMID:
20351326
4.

Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.

Seitz G, Warmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschner I, Fuchs J.

Pediatr Surg Int. 2007 May;23(5):431-9.

PMID:
17211591
5.

Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German Soft Tissue Sarcoma Cooperative Group.

Ferrari A, Bisogno G, Casanova M, Brecht IB, Alaggio R, Cecchetto G, Provenzi M, Koscielniak E, Treuner J, Carli M.

Pediatr Blood Cancer. 2004 Feb;42(2):134-8.

PMID:
14752876
6.

Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.

Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, Triche TJ.

J Clin Oncol. 2010 Oct 10;28(29):e587-8; author reply e589-90. doi: 10.1200/JCO.2010.30.5466. Epub 2010 Aug 9. No abstract available.

PMID:
20697086
7.

Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.

Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS.

J Clin Oncol. 2011 Apr 1;29(10):1304-11. doi: 10.1200/JCO.2010.29.4611. Epub 2011 Feb 28.

8.

Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation.

Wexler LH, Ladanyi M.

J Clin Oncol. 2010 May 1;28(13):2126-8. doi: 10.1200/JCO.2009.27.5339. Epub 2010 Mar 29. No abstract available.

PMID:
20351321
10.

Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.

Taulli R, Scuoppo C, Bersani F, Accornero P, Forni PE, Miretti S, Grinza A, Allegra P, Schmitt-Ney M, Crepaldi T, Ponzetto C.

Cancer Res. 2006 May 1;66(9):4742-9.

11.

Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.

Wolden SL, Lyden ER, Arndt CA, Hawkins DS, Anderson JR, Rodeberg DA, Morris CD, Donaldson SS.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1071-6. doi: 10.1016/j.ijrobp.2015.08.040. Epub 2015 Sep 5.

12.

Treatment Strategy for Pediatric Paratesticular Rhabdomyosarcoma Based on Chimeric Gene Assessment.

Unno R, Mizuno K, Ito Y, Etani T, Okada A, Kawai N, Yasui T, Saitoh S, Hayashi Y.

Urology. 2016 Sep;95:187-9. doi: 10.1016/j.urology.2016.03.024. Epub 2016 Mar 24.

PMID:
27017905
13.

Pattern of presentation and outcome of ophthalmic rhabdomyosarcoma in Ibadan.

Fasina O.

Afr J Med Med Sci. 2013 Jun;42(2):165-9.

PMID:
24377202
14.
15.

Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.

Ruymann FB, Grovas AC.

Cancer Invest. 2000;18(3):223-41. Review.

PMID:
10754991
16.

Rhabdomyosarcoma of the tongue.

Doval DC, Kannan V, Acharya RS, Mukherjee G, Shenoy AM, Bapsy PP.

Br J Oral Maxillofac Surg. 1994 Jun;32(3):183-6.

PMID:
8068593
17.

Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy.

Matsubara H, Makimoto A, Higa T, Kawamoto H, Takayama J, Ohira M, Yokoyama R, Beppu Y, Takaue Y.

Pediatr Hematol Oncol. 2003 Apr-May;20(3):201-10.

PMID:
12637216
18.

Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.

van Gaal JC, Roeffen MH, Flucke UE, van der Laak JA, van der Heijden G, de Bont ES, Suurmeijer AJ, Versleijen-Jonkers YM, van der Graaf WT.

Eur J Cancer. 2013 Nov;49(16):3462-70. doi: 10.1016/j.ejca.2013.06.022. Epub 2013 Jul 15.

PMID:
23867124
19.

GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.

Srivastava RK, Kaylani SZ, Edrees N, Li C, Talwelkar SS, Xu J, Palle K, Pressey JG, Athar M.

Oncotarget. 2014 Dec 15;5(23):12151-65.

20.

Supplemental Content

Support Center